Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer
Clinical trial NCT06837896 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06837896
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-01
- Primary completion
- 2026-11-01
- Enrollment
- 110
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.